Masahiro Yasunaga

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 14

Top Venues

Molecular pharmaceutics

ACS omega

ACS medicinal chemistry letters

Cancer immunology, immunotherapy : CII

National Cancer Centre

Kumamoto university (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Cancer Centre

Japan

Unit leader :: Developmental Therapeutics

National Cancer Center

Japan

Section Head :: Investigative Treatment Division

RIKEN Center for Developmental Biology

Japan

Researche :: Stem Cell Biology

School of Medicine Kumamoto University

Japan

Surgeon :: 1st department of Surgery

Yamaga City Hospital

Japan

Surgeon :: Surgery

Tsuruta Hospital

Japan

Surgeon :: Surgery

Shimonoseki Kousei Hospital

Japan

Surgeon :: Surgery

Education History

Kumamoto university

Japan

PHD :: School of medicine

Publications

Methanee Hiranyakorn, Shogo Iwamoto, Asako Hoshinoo, Ryo Tsumura, Hiroki Takashima, Masahiro Yasunaga, Shino Manabe
Chromatographic Analysis of the N -Glycan Profile on Therapeutic Antibodies Using FcγRIIIa Affinity Column Chromatography. ACS omega 8 (18) (2023)
Methanee Hiranyakorn, Shogo Iwamoto, Asako Hoshinoo, Ryo Tsumura, Hiroki Takashima, Masahiro Yasunaga, Shino Manabe
Chromatographic Analysis of the N -Glycan Profile on Therapeutic Antibodies Using FcγRIIIa Affinity Column Chromatography. ACS omega 8 (18) (2023)
Tomohiro Fujii, Kenichiro Ito, Kazutoshi Takahashi, Tsubasa Aoki, Rika Takasugi, Takuya Seki, Yusuke Iwai, Tomohiro Watanabe, Ryusuke Hirama, Ryo Tsumura, Hirobumi Fuchigami, Masahiro Yasunaga, Yutaka Matsuda
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation. ACS medicinal chemistry letters 14 (12) (2023)
Tomohiro Fujii, Kenichiro Ito, Kazutoshi Takahashi, Tsubasa Aoki, Rika Takasugi, Takuya Seki, Yusuke Iwai, Tomohiro Watanabe, Ryusuke Hirama, Ryo Tsumura, Hirobumi Fuchigami, Masahiro Yasunaga, Yutaka Matsuda
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation. ACS medicinal chemistry letters 14 (12) (2023)
Methanee Hiranyakorn, Shogo Iwamoto, Asako Hoshinoo, Ryo Tsumura, Hiroki Takashima, Masahiro Yasunaga, Shino Manabe
Chromatographic Analysis of the N -Glycan Profile on Therapeutic Antibodies Using FcγRIIIa Affinity Column Chromatography. ACS omega 8 (18) (2023)
Hiroki Takashima, Kazunobu Ohnuki, Shino Manabe, Yoshikatsu Koga, Ryo Tsumura, Takahiro Anzai, Yang Wang, Xiaojie Yin, Nozomi Sato, Yudai Shigekawa, Akihiro Nambu, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Masahiro Yasunaga
Tumor Targeting of 211 At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular pharmaceutics 20 (2) (2022)
Hiroki Takashima, Kazunobu Ohnuki, Shino Manabe, Yoshikatsu Koga, Ryo Tsumura, Takahiro Anzai, Yang Wang, Xiaojie Yin, Nozomi Sato, Yudai Shigekawa, Akihiro Nambu, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Masahiro Yasunaga
Tumor Targeting of 211 At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular pharmaceutics 20 (2) (2022)
Kazunobu Ohnuki, Mitsuyoshi Yoshimoto, Hiromitsu Haba, Shino Manabe, Hiroki Takashima, Masahiro Yasunaga, Yasumasa Takenaka, Hirofumi Fujii
Protection from contamination by 211 At, an enigmatic but promising alpha-particle-emitting radionuclide. EJNMMI physics 9 (1) (2022)
Hiroki Takashima, Kazunobu Ohnuki, Shino Manabe, Yoshikatsu Koga, Ryo Tsumura, Takahiro Anzai, Yang Wang, Xiaojie Yin, Nozomi Sato, Yudai Shigekawa, Akihiro Nambu, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Masahiro Yasunaga
Tumor Targeting of 211 At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular pharmaceutics 20 (2) (2022)
Hiroki Takashima, Kazunobu Ohnuki, Shino Manabe, Yoshikatsu Koga, Ryo Tsumura, Takahiro Anzai, Yang Wang, Xiaojie Yin, Nozomi Sato, Yudai Shigekawa, Akihiro Nambu, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Masahiro Yasunaga
Tumor Targeting of 211 At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular pharmaceutics 20 (2) (2022)
Hiroki Takashima, Kazunobu Ohnuki, Shino Manabe, Yoshikatsu Koga, Ryo Tsumura, Takahiro Anzai, Yang Wang, Xiaojie Yin, Nozomi Sato, Yudai Shigekawa, Akihiro Nambu, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Masahiro Yasunaga
Tumor Targeting of 211 At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular pharmaceutics (2022)
Hiroki Takashima, Yoshikatsu Koga, Shino Manabe, Kazunobu Ohnuki, Ryo Tsumura, Takahiro Anzai, Nozomi Iwata, Yang Wang, Takuya Yokokita, Yukiko Komori, Daiki Mori, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Yasuhiro Matsumura, Masahiro Yasunaga
Radioimmunotherapy with an 211 At-labeled anti-tissue factor antibody protected by sodium ascorbate. Cancer science 112 (5) (2021)
Daisuke Kamakura, Ryutaro Asano, Hiroki Kawai, Masahiro Yasunaga
Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation. Cancer immunology, immunotherapy : CII 70 (1) (2020)
Shigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, Takashi Kojima, Mayumi Yamauchi, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Masahiro Yasunaga, Yasuhiro Matsumura, Toshihiko Doi
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Molecular cancer therapeutics 18 (11) (2019)

Masahiro Yasunaga.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Masahiro Yasunaga